

# Targeting mitochondria by $\alpha$ -tocopheryl succinate kills neuroblastoma cells irrespective of *MycN* oncogene expression

Björn Kruspig · Azadeh Nilchian · Ignacio Bejarano ·  
Sten Orrenius · Boris Zhivotovsky · Vladimir Gogvadze

Received: 29 July 2011 / Revised: 17 December 2011 / Accepted: 5 January 2012 / Published online: 28 January 2012  
© Springer Basel AG 2012

**Abstract** Amplification of the *MycN* oncogene characterizes a subset of highly aggressive neuroblastomas, the most common extracranial solid tumor of childhood. However, the significance of *MycN* amplification for tumor cell survival is controversial, since down-regulation of *MycN* was found to decrease markedly neuroblastoma sensitivity towards conventional anticancer drugs, cisplatin, and doxorubicin. Here, we show that a redox-silent analogue of vitamin E,  $\alpha$ -tocopheryl succinate ( $\alpha$ -TOS), which triggers apoptotic cell death via targeting mitochondria, can kill tumor cells irrespective of their *MycN* expression level. In cells overexpressing *MycN*, as well as cells in which *MycN* was switched off,  $\alpha$ -TOS stimulated rapid entry of  $\text{Ca}^{2+}$  into the cytosol, compromised  $\text{Ca}^{2+}$  buffering capacity of the mitochondria and sensitized them towards mitochondrial permeability transition and subsequent apoptotic cell death. Prevention of mitochondrial  $\text{Ca}^{2+}$  accumulation or chelation of cytosolic  $\text{Ca}^{2+}$  rescued the cells. Thus, targeting mitochondria might be advantageous for the elimination of tumor cells with otherwise dormant apoptotic pathways.

**Keywords** Mitochondria · Apoptosis · Calcium · *MycN*

## Introduction

Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Amplification of the *MycN* oncogene characterizes a subset of highly aggressive NBs and correlates with poor prognosis in patients. *MycN* belongs to the *Myc* family of transcription factors that play a key role in the regulation of a variety of cellular processes, such as cell proliferation, differentiation, and apoptosis. The *Myc* gene is deregulated in a host of different tumors, including lung cancer, osteosarcoma, glioblastoma, breast and cervix carcinomas, myeloid and plasma cell leukemias, Burkitt's lymphoma and NB [1]. The views on the role and significance of *MycN* amplification for tumor cell survival are controversial. On the one hand, amplification of *MycN* characterizes a subset of rapidly proliferating and aggressive NBs. On the other, the ability of *MycN* to sensitize cells to apoptosis is well documented. Thus, downregulation of *MycN* markedly decreased NB cell sensitivity towards the DNA-damaging anticancer drugs cisplatin and doxorubicin, which makes *MycN* targeting in the treatment of patients problematic [2]. Identifying novel compounds that are equally efficient in tumor cells with different levels of *MycN* and/or p53 expression is therefore of critical importance for antitumor therapy.

Killing tumor cells is the ultimate aim of anticancer treatment. Among the different forms of cell death, the molecular mechanisms of apoptosis are so far the best characterized. Apoptosis is a gene-regulated mode of cell death responsible for cell deletion during embryogenesis

B. Kruspig · A. Nilchian · S. Orrenius · B. Zhivotovsky ·  
V. Gogvadze (✉)  
Division of Toxicology, Institute of Environmental Medicine,  
Karolinska Institutet, Box 210, 171 77 Stockholm, Sweden  
e-mail: vladimir.gogvadze@ki.se

I. Bejarano  
Department of Physiology, Faculty of Science,  
University of Extremadura, 06006 Badajoz, Spain

B. Zhivotovsky · V. Gogvadze  
MV Lomonosov Moscow State University,  
119991 Moscow, Russia

and maintenance of tissue homeostasis in the adult organism. Efficient anticancer therapy is based on the ability to stimulate dormant apoptotic pathways in tumor cells. Although it appears that different signals trigger distinct pathways leading to cell death, they often merge at a common regulator—the mitochondria. In particular, the release of pro-apoptotic proteins from the mitochondrial intermembrane space is regarded as a key event in apoptosis induction. Among these proteins are cytochrome *c*, apoptosis inducing factor (AIF), Smac/Diablo, and Omi (reviewed in [3]). Considering their role as key participants in the cell-death process, targeting of the mitochondria could contribute to tumor cell elimination. Therefore, sensitization of the mitochondria via manipulation of their energy metabolism, stimulation of reactive oxygen species (ROS) generation (or suppression of antioxidant capacity), or disruption of intracellular  $\text{Ca}^{2+}$  homeostasis might all contribute to more effective anticancer therapy [4].

Recently, a range of compounds, named mitocans (an abbreviation formed from MITOchondria and CANcer), were shown to cause cell death via targeting mitochondria [5].  $\alpha$ -Tocopheryl succinate ( $\alpha$ -TOS), a derivative of tocopherol, is one of the mitocans. In 1982, Prasad and Edwards-Prasad [6] reported for the first time that this redox-silent analogue of vitamin E induced morphological changes and growth inhibition in mouse melanoma cells. Further,  $\alpha$ -TOS was shown to inhibit the proliferation of avian reticuloendotheliosis virus-transformed lymphoblastoid cells in a dose-dependent manner, blocking the cells in the G2/M cell cycle phase, and to induce apoptosis [7].  $\alpha$ -TOS was also found to destabilize mitochondria, stimulating their production of ROS and to kill malignant cells at concentrations non-toxic to normal cells and tissues [8]. Although  $\alpha$ -tocopherol is known as an important chain-breaking antioxidant in cells, its derivative,  $\alpha$ -TOS, is apparently unable to act as an antioxidant unless the succinate moiety is cleaved off. It has been reported that non-malignant cells have the ability to hydrolyze  $\alpha$ -TOS by means of esterases, gradually releasing  $\alpha$ -tocopherol to prevent membrane oxidative damage [9], whereas in malignant cells the hydrolysis of  $\alpha$ -TOS is suppressed due to lower esterase activity [8, 10].

In the present study, we show that targeting mitochondria by  $\alpha$ -TOS overcomes the resistance of NB cells to treatment caused by *MycN* downregulation.  $\alpha$ -TOS caused mitochondrial destabilization followed by permeabilization of the outer mitochondrial membrane (OMM), release of pro-apoptotic proteins and activation of the downstream caspase cascade, irrespective of the cellular *MycN* or p53 expression levels. These findings support the use of  $\alpha$ -TOS as a tool in tumor cell elimination.

## Materials and methods

### Cells

Cells were cultured in RPMI 1640 complete medium supplemented with 10% (w/v) heat-inactivated fetal calf serum and penicillin/streptomycin (100 U/ml). For Tet21 N cells, 100  $\mu\text{g/ml}$  hygromycin and 200  $\mu\text{g/ml}$  geneticine was additionally added to the medium. Cells were grown in a humidified air/ $\text{CO}_2$  (5%) atmosphere at 37°C and maintained in a logarithmic growth phase for all experiments. A stock solution of  $\alpha$ -TOS (50 mM) was prepared by dissolving  $\alpha$ -TOS in ethanol. In order to analyze the significance of *MycN* for the sensitivity of Tet21 N cell towards apoptosis inducers, *MycN* expression was switched off by adding 0.1  $\mu\text{g/ml}$  of doxycycline (*MycN*(−) cells) [11].

### Estimation of mitochondrial activity in digitonin-permeabilized cells

Mitochondrial accumulation of  $\text{Ca}^{2+}$  was monitored with a  $\text{Ca}^{2+}$ -sensitive electrode (Thermo Scientific, Beverly, MA, USA). Cells were harvested and resuspended in 400  $\mu\text{l}$  of buffer (150 mM KCl, 5 mM  $\text{KH}_2\text{PO}_4$ , 1 mM  $\text{MgSO}_4$ , 5 mM succinate, 5 mM Tris, pH 7.4) and added to the  $\text{Ca}^{2+}$  electrode chamber. Following a 2-min stabilization period, cells were permeabilized with digitonin (5  $\mu\text{g}/10^6$  cells) and sequential pulses of  $\text{Ca}^{2+}$  (20 nmol each) were added to the permeabilized cells until mitochondrial permeability transition (MPT) was induced and accumulated  $\text{Ca}^{2+}$  released. The total amount of  $\text{Ca}^{2+}$  causing MPT was expressed as nmoles of  $\text{Ca}^{2+}/10^6$  cells.

### Assessment of cytochrome *c* release

Cells were digitonin-permeabilized and fractionated into supernatant and pellet. Samples were mixed with Laemmli's loading buffer, boiled for 5 min, and subjected to 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) at 40 mA followed by electroblotting to nitrocellulose for 2 h at 120 V. Membranes were blocked for 1 h with 5% nonfat milk in phosphate-buffered saline (PBS) at room temperature and subsequently probed overnight with a mouse anti-cytochrome *c* antibody (BD Biosciences, San Jose, CA). The membranes were rinsed and incubated with a horseradish peroxidase-conjugated secondary antibody (1:10,000). Blots were visualized by ECL<sup>TM</sup> (Amersham Biosciences, Buckinghamshire, UK) and X-ray film.

### Measurement of caspase-3-like activity

The measurement of DEVD-AMC (Peptide Institute, Osaka, Japan) cleavage was performed using a modified version of a fluorometric assay. Cells were pelleted and washed once with PBS. After centrifugation, cells were resuspended in PBS at a concentration of  $2 \times 10^6$  cells/100  $\mu$ l; 25  $\mu$ l of the suspension were added to a microtiter plate and mixed with the appropriate peptide substrate dissolved in a standard reaction buffer (100 mM HEPES, 10% sucrose, 5 mM DTT, 0.001% NP-40 and 0.1% CHAPS, pH 7.25). Cleavage of the fluorogenic peptide substrate was monitored by AMC liberation in a Fluoroscan II plate reader (Labsystems, Stockholm, Sweden) using 355-nm excitation and 460-nm emission wavelengths.

### Flow cytometry

Cell death was assessed using the Annexin V-FLUOS staining kit (Roche, Mannheim, Germany) according to the manufacturer's instructions.

### Morphological assessment of apoptosis

Cells were seeded on coverslips, fixed for 20 min in 4% formaldehyde at 4°C, and then washed with PBS. Nuclei were stained with HOECHST (2  $\mu$ g/ml) by 10-min incubation at room temperature. Stained slides were mounted using Vectashield H-1000 (Vector Laboratories Inc., Burlingame, CA, USA) and examined under a Zeiss LSM 510 META confocal laser scanner microscope.

### Live cell imaging

Tet21 N cells were incubated for 30 min (37°C, 5% CO<sub>2</sub>) in Krebs–Ringer solution containing 5  $\mu$ M Fluo-4/AM (Invitrogen-Molecular Probes, Eugene, OR). The Krebs–Ringer solution contained 119 mM NaCl, 2.5 mM KCl, 1.0 mM NaH<sub>2</sub>PO<sub>4</sub> (monobasic), 2.5 mM CaCl<sub>2</sub> 2H<sub>2</sub>O, 1.3 mM MgCl<sub>2</sub> 6H<sub>2</sub>O, 20 mM HEPES, 11 mM D-glucose (dextrose) C<sub>6</sub>H<sub>12</sub>O<sub>6</sub> and was adjusted to a pH of 7.4. After the incubation, cells were washed once with Krebs–Ringer solution and subsequently examined with a Zeiss LSM 510 META confocal laser scanning microscope. Images were acquired at 0.2 Hz and all drugs were bath-applied.

The amount of cytosolic H<sub>2</sub>O<sub>2</sub> in Tet21 N cells was assessed using the genetically encoded, targeted to cytosol fluorescent indicator pHyPer-dCyto (Evrogen, Moscow, Russia). Cells were seeded on coverslips and, on the following day, transiently transfected with pHyPer-dCyto using the Lipofectamine LTX/Plus reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. All experiments were performed using a Zeiss LSM

510 META confocal laser scanning microscope (Zeiss, Jena, Germany). For the time lapse, cells were cultivated in the POC-R cell cultivation system (Zeiss, Jena, Germany) at 37°C and humidified air/CO<sub>2</sub> (5%) atmosphere.  $\alpha$ -TOS was applied before start of the time lapse and fluorescence recorded for 16 h. Measurements were repeated three times and the H<sub>2</sub>O<sub>2</sub> production at 16 h after treatment expressed as  $x$ -fold increase in comparison with the starting point of the experiment.


## Results

### Downregulation of MycN attenuates apoptosis induced by cisplatin

Treatment of Tet21 N cells expressing *MycN* (*MycN*(+) cells) with 0.1  $\mu$ g/ml of doxycycline prevented the expression of *MycN* (*MycN*(−) cells) (Fig. 1a). Analysis of the response of Tet21 N cells to cisplatin revealed a marked difference between *MycN*(+) cells and *MycN*(−) cells. Switching off *MycN* prominently suppressed cisplatin-induced apoptosis, assessed by cytochrome *c* release (Fig. 1b), stimulation of caspase-3-like activity (Fig. 1c), and number of floating cells (Fig. 1d). Switching off *MycN* suppressed caspase-3 processing and cleavage of its downstream target PARP (Fig. 1e). In addition, downregulation of *MycN* markedly decreased the number of cisplatin-treated cells with apoptotic morphology (Fig. 1f). The dependence of cisplatin-induced apoptosis on *MycN* expression was confirmed by the analysis of phosphatidyl serine (PS) externalization, by staining with Annexin V and PI (Fig. 1g). Switching off *MycN* noticeably decreased the number of cells exposing PS on the outer surface of the plasma membrane (29.7 vs. 8.3%).

In order to clarify the mechanism of apoptosis suppression in *MycN*(−) cells, we analyzed the expression level of the transcription factor p53, which was shown to be a direct transcriptional target of *MycN* [12]. p53 is capable of launching an apoptotic program that includes direct transcriptional activation of death-inducing genes, such as *Noxa*, *Puma*, and *Bax* (reviewed in [13]). Treatment with cisplatin stimulated the expression of p53 in both *MycN*(+) and *MycN*(−) cells, although the level of p53 was distinctly lower in the *MycN*(−) cells (Fig. 1h). Further, analysis of the p53 phosphorylation status revealed a lower phosphorylation level of the serine 46 residue in *MycN*(−) cells, which is in agreement with recently published data on the significance of p53 phosphorylation for apoptosis in *MycN* overexpressing cells [14]; the extent of phosphorylation was correlated with the level of total p53 (Fig. 1h). Further, the expression of Bak, a pro-apoptotic Bcl-2 family protein, was also significantly lower in cisplatin-treated

**Fig. 1** Effect of *MycN* downregulation on apoptotic manifestations in Tet21 N cells treated with 10  $\mu\text{g/ml}$  cisplatin for 16 h. **a** Incubation of Tet21 N cells with 0.1  $\mu\text{g/ml}$  doxycycline blocks expression of *MycN* oncogene; **b** switching off *MycN* suppresses cytochrome *c* release, caspase-3-like activity (**c**), number of floating cells (**d**), processing of caspase-3 and PARP cleavage in response to 10  $\mu\text{g/ml}$  cisplatin (**e**), *black bars*: *MycN* overexpressing cells, *white bars*: *MycN* non-expressing Tet21 N cells,  $*p < 0.05$ ; **f** analysis of apoptotic morphology in cisplatin-treated *MycN*(+) and *MycN*(-) Tet21 N cells; *numbers* show the percentage of cells with apoptotic nuclei. Number of counted cells: 720 for *MycN*(+) cells and 450 for *MycN*(-) cells; **g** analysis of PS externalization in *MycN*(+) and *MycN*(-) Tet21 N cells in response to 10  $\mu\text{g/ml}$  cisplatin; **h** *upper blot*: 10  $\mu\text{g/ml}$  cisplatin-stimulated expression of p53 in *MycN*(+) and *MycN*(-) cells; *middle blot*: phosphorylation of p53; *lower blot*: cisplatin-induced expression of Bak



*MycN*(-) cells (Fig. 1h, lower blot). This may explain the suppression of cytochrome *c* release (Fig. 1b) as well as the processing and activation of caspase-3 and PARP cleavage in *MycN*(-) cells.

Downregulation of *MycN* does not affect apoptosis induced by  $\alpha$ -TOS


In contrast to cisplatin,  $\alpha$ -TOS induced apoptosis in Tet21 N cells irrespective of the status of *MycN*. Release of cytochrome *c*, caspase-3 processing and activity, as well as the number of floating cells were comparable, or even modestly enhanced, after switching *MycN* off (Fig. 2a–d). In addition to cytochrome *c*, release of AIF from mitochondria after  $\alpha$ -TOS treatment was also detected (Fig. 2e). Accordingly, the number of cells with apoptotic morphology was similar in both cell types: 55–60% (Fig. 2f).

$\alpha$ -TOS did not stimulate p53 expression as cisplatin did (Fig. 2g). Incubation with  $\alpha$ -TOS caused suppression in p53 expression. Accordingly, the content of Bak was also

reduced in both cell lines. It has been shown that  $\alpha$ -TOS-induced permeabilization of the OMM involves formation of Bax [10] or Bak channels, and that this process is modulated by Noxa, which is upregulated transcriptionally in a p53-independent manner [15]. Noxa can facilitate OMM permeabilization by displacing anti-apoptotic Bcl-2 family members from their complexes with other pro-apoptotic members, e.g., Bax. Incubation with  $\alpha$ -TOS stimulated the expression of Noxa more prominently in *MycN*(+) cells, as compared to *MycN*(-) cells (Fig. 2h). In spite of this, there was almost no difference in apoptosis manifestation between *MycN*(+) and *MycN*(-) cells. In addition, analysis of apoptotic changes in various NB cell lines with different levels of *MycN* expression [SK-N-AS, SK-N-SH, and SK-N-BE (2)] confirmed that OMM permeabilization, followed by release of cytochrome *c* and processing of caspase-3, was not dependent on *MycN* expression (Fig. 2i).

Another mechanism of OMM permeabilization, which can lead to the release of pro-apoptotic proteins from the

**Fig. 2** Effect of *MycN* downregulation on apoptotic manifestations in Tet21 N cells treated with 60  $\mu$ M  $\alpha$ -TOS for 16 h. **a**  $\alpha$ -TOS equally stimulates cell death assessed by the release of cytochrome *c* (**a**), caspase-3-like activity (**b**), the number of floating cells (**c**), and processing of caspase-3 (**d**) in *MycN*(+) (*black bars*) and *MycN*(-) (*white bars*) Tet21 N cells; **e**  $\alpha$ -TOS-induced release of AIF from mitochondria in *MycN*(+) and *MycN*(-) Tet21 N cells; **f** analysis of apoptotic morphology in  $\alpha$ -TOS-treated *MycN*(+) and *MycN*(-) Tet21 N cells. Numbers show the percentage of cells with apoptotic nuclei. Number of counted cells: 560 for *MycN*(+) cells and 260 for *MycN*(-) cells; **g** *upper blot*: p53 expression, *lower blot*: Bak expression in  $\alpha$ -TOS treated *MycN*(+) and *MycN*(-) Tet21 N cells; **h** switching off *MycN* attenuated  $\alpha$ -TOS-induced expression of Noxa; **i**  $\alpha$ -TOS-induced cytochrome *c* release, caspase-3 cleavage, and *MycN* expression in various NB cells. *Lower blot*: loading control



mitochondrial intermembrane space, is the induction of MPT due to opening of a non-specific pore (MPT pore) in the inner mitochondrial membrane (IMM) [16]. A prerequisite step for pore opening is the accumulation of  $\text{Ca}^{2+}$  by the mitochondria; thus, an increase in cytosolic  $\text{Ca}^{2+}$  level facilitates MPT induction. We have shown earlier that  $\alpha$ -TOS can stimulate cellular  $\text{Ca}^{2+}$  uptake, resulting in MPT induction [17]. Analysis of  $\alpha$ -TOS-induced cytosolic  $\text{Ca}^{2+}$  transients did not reveal any difference between *MycN*(+) and *MycN*(-) cells (Fig. 3a). In both cell types, the addition of  $\alpha$ -TOS led to a rapid increase in cytosolic  $\text{Ca}^{2+}$  concentration with subsequent normalization within a few minutes. Chelation of cytosolic  $\text{Ca}^{2+}$  by BAPTA markedly decreased


the amplitude of the  $\text{Ca}^{2+}$  response to  $\alpha$ -TOS. When extracellular  $\text{Ca}^{2+}$  was quenched by EGTA, the cytosolic  $\text{Ca}^{2+}$  increase diminished markedly, but not completely, indicating that release of  $\text{Ca}^{2+}$  from the endoplasmic reticulum might contribute to the  $\alpha$ -TOS-induced  $\text{Ca}^{2+}$  transients. Dissipation of the mitochondrial membrane potential (the main driving force for  $\text{Ca}^{2+}$  accumulation) by the uncoupler CCCP prevented normalization of the  $\text{Ca}^{2+}$  level in the cytosol, indicating that it was dependent on  $\text{Ca}^{2+}$  accumulation by the mitochondria [17]. This was found to be critical for the apoptotic response, since chelation of cytosolic  $\text{Ca}^{2+}$  by BAPTA significantly suppressed the  $\alpha$ -TOS-induced caspase-3-like activity (Fig. 3b).

A powerful factor sensitizing mitochondria to MPT is oxidative stress. In view of the ability of  $\alpha$ -TOS to stimulate ROS production [8], analysis of ROS production in *MycN*(+) and *MycN*(-) cells was performed using genetically encoded, targeted to cytosol fluorescent indicator pHyPer-dCyto, as described in “Materials and methods”. Figure 3c demonstrates confocal images of cells treated with 60  $\mu$ M  $\alpha$ -TOS for 16 h, and Fig. 3d shows a fold increase in ROS content in *MycN*(+) and *MycN*(-) cells. In both cases,  $\alpha$ -TOS-induced oxidative stress was comparable. In addition, the depletion of thiols was assessed in *MycN*(+) and *MycN*(-) cells as a marker of oxidative stress. Incubation of cells with  $\alpha$ -TOS for 16 h decreased the level of thiols in both cell lines to the same extent; this

effect was preventable by the antioxidant *N*-acetylcysteine (NAC). (Fig. 3e).  $\alpha$ -TOS-induced oxidative stress is important for apoptosis induction since NAC prominently decreased  $\alpha$ -TOS-mediated caspase-3 activation (Fig. 3f). Similarly, caspase-3-like activity in  $\alpha$ -TOS-treated cells was diminished by cyclosporin A (CsA), an inhibitor of the MPT pore (Fig. 3f, dashed bar), indicating that execution of apoptosis involves MPT induction.

It appears from these findings that exposure to  $\alpha$ -TOS is likely to make mitochondria more sensitive to MPT pore opening. Indeed, analysis of mitochondrial  $\text{Ca}^{2+}$  buffering capacity revealed that treatment with  $\alpha$ -TOS markedly reduced the threshold level of  $\text{Ca}^{2+}$ , required for MPT induction. In these experiments, cells were treated with

**Fig. 3** Alteration of cytosolic and mitochondrial  $\text{Ca}^{2+}$  homeostasis in NB cells. **a** 60  $\mu$ M  $\alpha$ -TOS stimulates  $\text{Ca}^{2+}$  transients in *MycN*(+) and *MycN*(-) cells. **b** Chelation of intracellular  $\text{Ca}^{2+}$  by BAPTA AM attenuates caspase-3-like activity in Tet21 N cells,  $*p < 0.05$ ; **c** ROS accumulation in *MycN*(+) cells treated with 60  $\mu$ M  $\alpha$ -TOS for 16 h. **d** Fold increase in ROS content after 16 h incubation of *MycN*(+) and *MycN*(-) cells with 60  $\mu$ M  $\alpha$ -TOS,  $*p < 0.05$ . The results were calculated as average from at least ten responding cells. **e** Incubation with 60  $\mu$ M  $\alpha$ -TOS for 16 h decreases the content of SH-groups in NB cells; NAC, 5 mM,  $*p < 0.05$ ; **f** NAC and cyclosporin A (5  $\mu$ M) prevent  $\alpha$ -TOS-mediated stimulation of caspase-3-like activity



60  $\mu$ M  $\alpha$ -TOS or 10  $\mu$ g/ml cisplatin for 16 h, harvested, and resuspended in KCl-based buffer containing succinate as a mitochondrial substrate (see “Materials and methods”). After a 2-min period of stabilization, the plasma membrane was permeabilized with digitonin (5  $\mu$ g/10<sup>6</sup> cells). Addition of  $\text{Ca}^{2+}$  to the permeabilized cells led to a rapid increase in the level of this cation in the incubation buffer followed by a return to the initial level (Fig. 4a) as mitochondria accumulated the added  $\text{Ca}^{2+}$ . Mitochondria took up sequential additions of  $\text{Ca}^{2+}$  until MPT was induced and  $\text{Ca}^{2+}$  was released. The threshold level of  $\text{Ca}^{2+}$  required for MPT induction (calcium capacity) was calculated by summation of all  $\text{Ca}^{2+}$  pulses. Administration of  $\alpha$ -TOS caused similar suppression of the mitochondrial  $\text{Ca}^{2+}$  capacity in both *MycN*(+) and *MycN*(-) Tet21 N cells (Fig. 4b). In contrast, *MycN*(-) cells treated with cisplatin did not show any significant decrease in  $\text{Ca}^{2+}$  capacity. The difference between cisplatin-treated *MycN*(+) and *MycN*(-) cells correlates with the amount of cytochrome *c* released from their mitochondria. These results demonstrate that treatment with  $\alpha$ -TOS sensitizes mitochondria to MPT induction, and that the mitochondria are equally susceptible to  $\text{Ca}^{2+}$ -mediated pore opening irrespective of *MycN* status. This is in accordance with the finding of comparable amounts of cytochrome *c* release from the mitochondria in  $\alpha$ -TOS-treated *MycN*(+) and *MycN*(-) Tet21 N cells.


## Discussion

The results presented here show that the consequences of *MycN* downregulation for the susceptibility of tumor cells

to undergo apoptosis depend on the type of apoptosis inducer. In case of cisplatin, downregulation of *MycN* attenuates cell death, whereas  $\alpha$ -TOS-induced apoptosis is not affected.

Two main mechanisms of OMM permeabilization—Bax/Bak-dependent and MPT-dependent—can be responsible for the release of mitochondrial pro-apoptotic proteins during apoptosis. In case of cisplatin, damage to DNA leads to stimulation of p53 expression and subsequent transcription of a number of pro-apoptotic proteins, including those involved in OMM permeabilization. Switching off *MycN* suppresses cisplatin-induced p53 expression and, as a result thereof, attenuates apoptotic manifestations.

Pro-apoptotic Bcl-2 family proteins have been reported to also be involved in  $\alpha$ -TOS-induced apoptosis. Thus,  $\alpha$ -TOS-stimulated production of ROS was suggested to be responsible for the formation of disulfide bridges between cytosolic Bax monomers, facilitating OMM permeabilization and cytochrome *c* release [10]. Moreover,  $\alpha$ -TOS was reported to cause conformational changes in the pro-apoptotic protein Bak, involving its oligomerization, in various cell types [15]. In addition,  $\alpha$ -TOS stimulated the expression of Noxa, a pro-apoptotic member of the Bcl-2 family [18], in a FoxO1-dependent manner [19]. Noxa facilitates OMM permeabilization by displacing anti-apoptotic Bcl-2 proteins from their complexes with pro-apoptotic family members. Switching off *MycN* suppressed the  $\alpha$ -TOS-induced expression of Noxa. However, the lower expression of Noxa in *MycN*(-) cells, as compared to *MycN*(+) cells, did not attenuate  $\alpha$ -TOS-induced apoptosis, suggesting that in addition to Noxa expression, other mechanisms of OMM permeabilization might be more important for the outcome of  $\alpha$ -TOS treatment.



**Fig. 4** Mitochondrial  $\text{Ca}^{2+}$  accumulation in NB cells with different level of *MycN* expression. **a** Accumulation of  $\text{Ca}^{2+}$  by mitochondria in digitonin-permeabilized *MycN*(+) cells. Pulses of  $\text{Ca}^{2+}$  (20 nmol) were added sequentially until MPT was induced and the accumulated

$\text{Ca}^{2+}$  was released; **b** effect of 60  $\mu$ M  $\alpha$ -TOS and 10  $\mu$ g/ml cisplatin on mitochondrial  $\text{Ca}^{2+}$  capacity (the threshold level of  $\text{Ca}^{2+}$  required for MPT induction) in *MycN*(+) and *MycN*(-) Tet21 N cells, \* $p < 0.05$

Recently, we reported that  $\alpha$ -TOS also activates the MPT-dependent pathway of OMM permeabilization [17]. Together with Bax/Bak-mediated pore formation, this mechanism might be responsible for  $\alpha$ -TOS-mediated OMM permeabilization; in particular, release of cytochrome *c* and stimulation of caspase-3-like activity were observed in mouse embryonic fibroblasts lacking both Bax and Bak. Hence,  $\alpha$ -TOS-mediated  $\text{Ca}^{2+}$  influx into NB cells and its subsequent accumulation in the mitochondria was suggested to destabilize these organelles and facilitate MPT. The mitochondrial  $\text{Ca}^{2+}$  accumulation was important for apoptosis progression, as inhibition of mitochondrial  $\text{Ca}^{2+}$  uptake by CCCP, or chelation of intracellular  $\text{Ca}^{2+}$  by BAPTA (Fig. 3b), significantly mitigated the apoptotic response.

Which mechanism is predominant in OMM permeabilization is cell-type dependent. We believe that both mechanisms are important for OMM permeabilization. Moreover, there is a certain coordination between them. Thus, as we have shown earlier, treatment of isolated rat liver mitochondria with Bax resulted in stimulation of MPT [20]. In digitonin-permeabilized Tet21 N cells tBid-mediated permeabilization of OMM sensitized mitochondria to  $\text{Ca}^{2+}$  loading [17]. Apparently, Bax does not participate directly in  $\text{Ca}^{2+}$ -mediated permeability transition [21], but Bax and MPT were shown to cooperate in the release of cytochrome *c* during endoplasmic reticulum stress-induced apoptosis [22]. Collaboration of the two pathways in OMM permeabilization has been confirmed recently by Brustovetsky et al. [23]. The authors showed that recombinant Bax readily integrates and oligomerizes in the OMM in isolated brain mitochondria, but produces only a minute release of cytochrome *c*. In contrast,  $\text{Ca}^{2+}$  and Bax together caused CsA-preventable substantial release of cytochrome *c*, while  $\text{Ca}^{2+}$  alone was not effective. Accumulation of  $\text{Ca}^{2+}$  is a prerequisite step for MPT induction. Indeed, perturbation of intracellular  $\text{Ca}^{2+}$  homeostasis can cause cytotoxicity and trigger either apoptotic or necrotic cell death [24]. However, MPT might also occur under normal physiological conditions, especially in mitochondria located in close proximity to calcium “hot spots”, microdomains in which the local concentration of ionized calcium by far exceeds the average concentration measured throughout the cytosol [25]. This local  $\text{Ca}^{2+}$  concentration might be high enough to induce mitochondrial  $\text{Ca}^{2+}$  overload and subsequent pore opening. Further, compounds affecting mitochondrial function, e.g., mitochondrial respiration and production of ROS, or interacting with components of the MPT pore machinery, can compromise mitochondrial  $\text{Ca}^{2+}$  buffering capacity and decrease the threshold level of  $\text{Ca}^{2+}$  that is normally required for MPT induction. Various compounds, such as ceramide metabolites [26] or palmitate [27], can sensitize mitochondria

towards permeability transition. In such conditions, MPT induction and initiation of cell death might also occur in the absence of any significant disruption of intracellular  $\text{Ca}^{2+}$  homeostasis [28].

$\alpha$ -TOS triggered cellular  $\text{Ca}^{2+}$  uptake by NB cells, which was unaffected by the level of *MycN* expression. The influx of  $\text{Ca}^{2+}$  was followed by its accumulation in mitochondria, induction of MPT, and OMM permeabilization. In addition, the degree of thiol oxidation was similar in  $\alpha$ -TOS-treated *MycN*(+) and *MycN*(−) Tet21 N cells; oxidative stress sensitizes mitochondria towards permeability transition [29]. Therefore, it appears that MPT largely contributes to OMM permeabilization in  $\alpha$ -TOS-induced apoptosis. This is triggered by the influx of extracellular  $\text{Ca}^{2+}$  and its subsequent accumulation in the mitochondria. MPT induction is further facilitated by the enhanced ROS production and inhibition of maximal respiratory chain capacity by  $\alpha$ -TOS. None of these effects of  $\alpha$ -TOS treatment is dependent on the *MycN* status of the cells, which also does not influence their susceptibility to undergo  $\alpha$ -TOS-induced apoptosis.

Although the precise mechanisms of  $\alpha$ -TOS action remain to be further investigated, the results obtained so far make it an attractive candidate for antitumor therapy. It has been demonstrated that  $\alpha$ -TOS can affect the mitochondrial respiratory chain through interaction with the CoQ-binding site of Complex II. Targeting of Complex II by  $\alpha$ -TOS was demonstrated in experiments with xenografts derived from Chinese hamster lung fibroblasts with functional, dysfunctional, and reconstituted Complex II, which revealed that the growth of Complex II-functional and Complex II-reconstituted tumors was strongly suppressed by  $\alpha$ -TOS, and that this was accompanied by a high level of apoptosis induction in the tumor cells [30]. Hence, targeting mitochondria by mitocans might be advantageous for the elimination of tumor cells with otherwise dormant apoptotic pathways.

**Acknowledgments** The authors are indebted to Prof. Marie Henriksson (Karolinska Institutet, Stockholm) and Dr. John Inge Johnsen (Karolinska Institutet, Stockholm) for providing the cell lines used in the study. The work was supported by grants from the Swedish Research Council, the Swedish and the Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation, the EC FP-6 (Chemores), the Russian Ministry of High Education and Science (11.G34.31.0006), and the EC FP7 (Apo-Sys) programs.

## References

1. Cole MD, Henriksson M (2006) 25 years of the c-Myc oncogene. *Semin Cancer Biol* 16:241. doi:10.1016/j.semcancer.2006.08.003
2. Fulda S, Lutz W, Schwab M, Debatin KM (1999) *MycN* sensitizes neuroblastoma cells for drug-induced apoptosis. *Oncogene* 18:1479–1486. doi:10.1038/sj.onc.1202435

3. Gogvadze V, Orrenius S, Zhivotovsky B (2006) Multiple pathways of cytochrome c release from mitochondria in apoptosis. *Biochim Biophys Acta* 1757:639–647. doi:[10.1016/j.bbabo.2006.03.016](https://doi.org/10.1016/j.bbabo.2006.03.016)
4. Hagland H, Nikolaisen J, Hodneland LI, Gjertsen BT, Bruserud O, Tronstad KJ (2007) Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. *Expert Opin Ther Targets* 11:1055–1069. doi:[10.1517/14728222.11.8.1055](https://doi.org/10.1517/14728222.11.8.1055)
5. Ralph SJ, Neuzil J (2009) Mitocans, a class of emerging anti-cancer drugs. *Mol Nutr Food Res* 53:7–8. doi:[10.1002/mnfr.200890054](https://doi.org/10.1002/mnfr.200890054)
6. Prasad KN, Edwards-Prasad J (1982) Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. *Cancer Res* 42:550–555
7. Qian M, Sanders BG, Kline K (1996) RRR- $\alpha$ -tocopheryl succinate induces apoptosis in avian retrovirus-transformed lymphoid cells. *Nutr Cancer* 25:9–26
8. Ottino P, Duncan JR (1997) Effect of  $\alpha$ -tocopherol succinate on free radical and lipid peroxidation levels in BL6 melanoma cells. *Free Radic Biol Med* 22:1145–1151 (pii:S0891584996005291)
9. Fariss MW, Nicholls-Grzemeski FA, Tirmenstein MA, Zhang JG (2001) Enhanced antioxidant and cytoprotective abilities of vitamin E succinate is associated with a rapid uptake advantage in rat hepatocytes and mitochondria. *Free Radic Biol Med* 31:530–541 (pii:S0891584901006153)
10. Neuzil J, Wang XF, Dong LF, Low P, Ralph SJ (2006) Molecular mechanism of ‘mitocan’-induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins. *FEBS Lett* 580:5125–5129. doi:[10.1016/j.febslet.2006.05.072](https://doi.org/10.1016/j.febslet.2006.05.072)
11. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M (1996) Conditional expression of *N-myc* in human neuroblastoma cells increases expression of  $\alpha$ -prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. *Oncogene* 13:803–812
12. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA (2010) p53 is a direct transcriptional target of MYCN in neuroblastoma. *Cancer Res* 70:1377–1388. doi:[10.1158/0008-5472.CAN-09-2598](https://doi.org/10.1158/0008-5472.CAN-09-2598)
13. Junttila MR, Evan GI (2009) p53—a Jack of all trades but master of none. *Nat Rev Cancer* 9:821–829. doi:[10.1038/nrc2728](https://doi.org/10.1038/nrc2728)
14. Petroni M, Veschi V, Prodosmo A, Rinaldo C, Massimi I, Carbonari M, Dominici C, McDowell HP, Rinaldi C, Screpanti I, Frati L, Bartolazzi A, Gulino A, Soddu S, Giannini G (2011) MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response. *Mol Cancer Res* 9:67–77. doi:[10.1158/1541-7786.MCR-10-0227](https://doi.org/10.1158/1541-7786.MCR-10-0227)
15. Prochazka L, Dong LF, Valis K, Freeman R, Ralph SJ, Turanek J, Neuzil J (2010)  $\alpha$ -Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. *Apoptosis* 15:782–794. doi:[10.1007/s10495-010-0482-z](https://doi.org/10.1007/s10495-010-0482-z)
16. Crompton M (1999) The mitochondrial permeability transition pore and its role in cell death. *Biochem J* 341:233–249
17. Gogvadze V, Norberg E, Orrenius S, Zhivotovsky B (2010) Involvement of  $\text{Ca}^{2+}$  and ROS in  $\alpha$ -tocopheryl succinate-induced mitochondrial permeabilization. *Int J Cancer* 127:1823–1832. doi:[10.1002/ijc.25204](https://doi.org/10.1002/ijc.25204)
18. Valis K, Prochazka L, Boura E, Chladova J, Obsil T, Rohlena J, Truksa J, Dong LF, Ralph SJ, Neuzil J (2011) Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner. *Cancer Res* 71:946–954. doi:[10.1158/0008-5472.CAN-10-2203](https://doi.org/10.1158/0008-5472.CAN-10-2203)
19. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. *Science* 288:1053–1058 (pii:8508)
20. Gogvadze V, Robertson JD, Zhivotovsky B, Orrenius S (2001) Cytochrome c release occurs via  $\text{Ca}^{2+}$ -dependent and  $\text{Ca}^{2+}$ -independent mechanisms that are regulated by Bax. *J Biol Chem* 276:19066–19071. doi:[10.1074/jbc.M100614200](https://doi.org/10.1074/jbc.M100614200)
21. De Marchi U, Campello S, Szabo I, Tombola F, Martinou JC, Zoratti M (2004) Bax does not directly participate in the  $\text{Ca}^{2+}$ -induced permeability transition of isolated mitochondria. *J Biol Chem* 279:37415–37422. doi:[10.1074/jbc.M314093200](https://doi.org/10.1074/jbc.M314093200)
22. Zhang D, Armstrong JS (2007) Bax and the mitochondrial permeability transition cooperate in the release of cytochrome c during endoplasmic reticulum-stress-induced apoptosis. *Cell Death Differ* 14:703–715. doi:[10.1038/sj.cdd.4402072](https://doi.org/10.1038/sj.cdd.4402072)
23. Brustovetsky T, Li T, Yang Y, Zhang JT, Antonsson B, Brustovetsky N (2010) BAX insertion, oligomerization, and outer membrane permeabilization in brain mitochondria: role of permeability transition and SH-redox regulation. *Biochim Biophys Acta* 1797:1795–1806. doi:[10.1016/j.bbabo.2010.07.006](https://doi.org/10.1016/j.bbabo.2010.07.006)
24. Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the calcium-apoptosis link. *Natl Rev Mol Cell Biol* 4:552–565. doi:[10.1038/nrm1150](https://doi.org/10.1038/nrm1150)
25. Rizzuto R, Brini M, Murgia M, Pozzan T (1993) Microdomains with high  $\text{Ca}^{2+}$  close to  $\text{IP}_3$ -sensitive channels that are sensed by neighboring mitochondria. *Science* 262:744–747
26. Pinton P, Ferrari D, Rappizzi E, Di Virgilio F, Pozzan T, Rizzuto R (2001) The  $\text{Ca}^{2+}$  concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. *EMBO J* 20:2690–2701. doi:[10.1093/emboj/20.11.2690](https://doi.org/10.1093/emboj/20.11.2690)
27. Koshkin V, Dai FF, Robson-Doucette CA, Chan CB, Wheeler MB (2008) Limited mitochondrial permeabilization is an early manifestation of palmitate-induced lipotoxicity in pancreatic beta-cells. *J Biol Chem* 283:7936–7948. doi:[10.1074/jbc.M705652200](https://doi.org/10.1074/jbc.M705652200)
28. Hajnoczky G, Csordas G, Das S, Garcia-Perez C, Saotome M, Roy SS, Yi M (2006) Mitochondrial calcium signalling and cell death: approaches for assessing the role of mitochondrial  $\text{Ca}^{2+}$  uptake in apoptosis. *Cell Calcium* 40:553–560. doi:[10.1016/j.ceca.2006.08.016](https://doi.org/10.1016/j.ceca.2006.08.016)
29. Costantini P, Chernyak BV, Petronilli V, Bernardi P (1996) Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. *J Biol Chem* 271:6746–6751
30. Dong LF, Freeman R, Liu J, Zabalova R, Marin-Hernandez A, Stantic M, Rohlena J, Valis K, Rodriguez-Enriquez S, Butcher B, Goodwin J, Brunk UT, Witting PK, Moreno-Sanchez R, Scheffler IE, Ralph SJ, Neuzil J (2009) Suppression of tumor growth in vivo by the mitocan  $\alpha$ -tocopheryl succinate requires respiratory complex II. *Clin Cancer Res* 15:1593–1600. doi:[10.1158/1078-0432.CCR-08-2439](https://doi.org/10.1158/1078-0432.CCR-08-2439)